Author + information
- Received October 22, 1990
- Accepted December 10, 1990
- Published online May 1, 1991.
- J.Richard Spears, MD, FACC∗,
- Sourav K. Kundu, PhD and
- Linda P. McMath, MS
- ↵∗Address for reprints: J. Richard Spears, MD, Cardiac Laser Laboratory, Louis M. Elliman Building, Wayne State University School of Medicine, 421 East Canfield Road, Detroit, Michigan 48201.
Mitigation of adverse biologic reactivity after balloon angioplasty is necessary before the incidence of restenosis can be appreciably reduced. A brief review of experimental evidence supports the hypothesis that the thrombogenicity of the injured arterial wall can be reduced by a suitable level of thermal denaturation or cross-linking of thrombogenic proteins. In addition, the concept of local pharmacologic therapy, which can be provided with laser balloon angioplasty at the site of arterial injury, is introduced.
Preliminary in vitro and in vivo data suggest that guide catheter-injected albumin-heparin conjugates fabricated as waterinsoluble microspheres remain adherent to the injured luminal surface and deeper arterial layers after physical trapping by the inflated balloon and subsequent laser/thermal exposure. The combination of initially adequate luminal morphology, reduction of the thrombogenicity of the injured arterial wall and application of local pharmacologic therapy with laser balloon angioplasty may eventually prove helpful in reducing the incidence of restenosis.
☆ This work was supported in pan by Grant HL-37349 from the Natural Heart, Lung, and Blood Institute, Bethesda, Maryland.
- Received October 22, 1990.
- Accepted December 10, 1990.